A LIGNAN FROM SCHIZANDRA CHINENSIS*

YUKINOBU IKEYA, HEIHACHIRO TAGUCHI, HIROSHI MITSUHASHI, SHIGEFUMI TAKEDA†, YOSHIO KASE† and MASAKI Aburada†

Tsumura Laboratory, 3586 Yoshiwara Ami-Machi, Inashiki-Gun, Ibaraki, Japan; †Tsumura Research Institute for Pharmacology, 3586 Yoshiwara Ami-Machi, Inashiki-Gun, Ibaraki, Japan

(Revised received 17 June 1987)

Key Word Index—Schizandra chinensis.; Schizandraceae; dibenzocyclooctadiene; lignan; isoschizandrin; anti-ulcer effect.

Abstract—A new dibenzocyclooctadiene lignan, isoschizandrin was isolated from the fruits of *Schizandra chinensis*. The structure was elucidated on the basis of the spectral analysis and chemical correlation with schizandrin and (+)-deoxyschizandrin. In experiments using rats, schizandrin and its derivatives, including isoschizandrin, showed inhibitory effects on stress-induced gastric ulceration (p.o.).

INTRODUCTION

Thirty-four dibenzocyclooctadiene lignans[1] have been isolated from the fruits of *Schizandra chinensis* Baill. This paper deals with the isolation and structure elucidation of the new lignan, isoschizandrin (1a) and its inhibitory effect on stress-induced gastric ulceration.

RESULTS AND DISCUSSION

Isoschizandrin (1a) was obtained as a white amorphous powder, $C_{24}H_{32}O_7$, $[\alpha]_D + 92^\circ$ (CHCl₃). The UV, IR, ¹H NMR (Table 1) and ¹³C NMR (Table 2) spectra of 1a indicated that 1a was a dibenzocyclooctadiene lignan possessing the same functional groups as schizandrin (1b) [2], namely, six methoxyl groups on the aromatic rings, a tertiary methyl group attached to a carbon carrying a hydroxyl group, a secondary methyl group and two benzylic methylenes.

The constitution of **1a** was assumed by the ¹H-¹³C shift correlated spectrum obtained by the correlation spectroscopy via long range coupling (COLOC) as shown in Fig. 1. The stereostructure of 1a was elucidated by the measurements of the intramolecular nuclear Overhauser effect (NOE) in CDCl₃ as in the case of 1b[2]. Irradiation of the methoxyl (δ 3.89), H-9 α (2.32) and tertiary methyl (1.19) groups caused 18, 12, 9% enhancements in the integrated intensity of the H-11 signal (6.62), respectively. On the other hand, no enhancement of the intensity of the H-4 signal ($\delta 6.54$) was detected upon irradiation of the C-7-secondary methyl signal (0.89). These findings indicate that the C-8 tertiary methyl group and H-11 are close to each other, while the C-7 secondary methyl group and H-4 are not. From these NOE data, the stereostructure of isoschizandrin was suggested as 1a possessing a twistboat-chair conformation of the cyclooctadiene ring.

The structure of 1a including the biphenyl configuration was confirmed by the chemical correlation with (+)-deoxyschizandrin (1c) [3] and schizandrin (1b). Treatment of **1a** with phosphorus oxychloride in dry pyridine afforded 2, $C_{24}H_{30}O_6$. The ¹H NMR spectrum of 2 in CDCl₃ showed two doublet signals (δ 4.73 and 4.86, each d, J = 2 Hz) due to an exo-methylene group. Catalytic hydrogenation of 2 afforded (+)-deoxyschizandrin (1c), possessing a 7,8-cis-dimethyl group, and 1d. A comparison of the ¹H NMR and ¹³C NMR spectra of 1d with those of trans-5,6,7,8-tetrahydro-1,12-dimethoxy-2,3:10,11-bis (methylenedioxy)-6,7-dimethylbenzo [a, c]cyclooctene (3) synthesized by Tobinaga et al. [4] showed that 1d possesses the same 7,8-trans-dimethyl group as 3. The reaction mechanism requiring that hydrogenation of 2 occurs from the C-8 α ,17 α side to afford 1d, was confirmed by the finding that deuteration of 2 afforded 1e $(8\alpha, 17$ -dideutero compound of 1d) and a minor compound which had a RR_t on HPLC the same as that of 1c. By the chemical correlation of 1a and 1c, the configuration of the C-7 position in 1a was determined to be R and that of the biphenyl group was also determined to be R.

Finally, the configuration of the C-8 position in 1a was confirmed by the transformation of schizandrin (1b) to 1a as follows. Treatment of 1b with phosphorous oxychloride in dry pyridine afforded a dehydrated product (4a) [5] which showed no hydroxyl band in the IR spectrum. The ¹H NMR spectrum of 4a in CDCl₃ showed an olefinic proton signal ($\delta 6.19$, br s) and an olefinic methyl signal ($\delta 1.63$, d, J = 1.5 Hz), indicating the presence of the partial structure (Ar-CH=C-Me). On oxidation with selenium dioxide in dioxane followed by

dation with selenium dioxide in dioxane followed by acetylation 4a afforded 4b, $C_{24}H_{30}O_7$ and 4c, $C_{26}H_{32}O_8$. The ¹H NMR spectrum of 4b in C_6D_6 showed an olefinic methyl signal ($\delta 1.76$, s) and a tertiary methyl signal (1.47, s) attached to a carbon carrying a hydroxyl group (1.54), indicating that a hydroxyl group was attached to the C-8 carbon of 4a. The configuration of the C-8 methyl group

^{*}Part 14 in the series 'The Constituents of Schizandra chinensis Baill'; for Part 13 see ref. [1].



2

1a $R^1 = H, R^2 = R^4 = Me, R^3 = OH$ **1b** $R^1 = OH$, $R^2 = R^4 = Me$, $R^3 = H$ 1c $R^1 = R^3 = H$, $R^2 = R^4 = Me$ **1d** $R^1 = R^4 = H$, $R^2 = R^3 = Me$ 1e $R^1 = H$, $R^2 = Me$, $R^3 = CH_2D$, $R^4 = D$





		Table 1. THYMR spectral data of compou				
Compound	H-4, s H-11, s	$\begin{array}{l} \text{H-6}\alpha\\ (J=\text{Hz}) \end{array}$	$\begin{array}{l} \text{H-6}\beta\\ (J = \text{Hz}) \end{array}$	$\begin{array}{l} H-9\alpha\\ (J=Hz) \end{array}$	$\begin{array}{l} \text{H-9}\beta\\ (J=\text{Hz}) \end{array}$	
1a*	6.54	2.53, d(1.8)		2.32, dd	2.82, d	
	6.52	2.54, s		(13.1, 0.8)	(13.1)	
1a†	6.40	2.38, dd	2.63, dd	2.25, d	2.96, d	
	6.48	(14, 8)	(14, 1.5)	(13)	(13)	
1b	6.60	2.70, d	2.32, d	2.33, dd	2.68, dd	
	6.53	(14)	(14)	(14, 7)	(14, 2)	
1c‡	6.51	2.52 (centre)		2.27, dd	2.02, dd	
	(× 2)	(2H, m)		(13.5, 9)	(13.5, 1)	
1d	6.53	2.34, dd	2.53, dd	2.53, dd	2.34, dd	
	(×2)	(13.5, 7)	(13.5, 1.5)	(13.5, 1.5)	(13.5, 7)	
1e	6.52	2.34, dd	2.53, dd	2.56, d	2.32, d	
	(× 2)	(13.5, 7)	(13.5, 1.5)	(13.5)	(13.5)	
3‡	6.48	2.25, dd	2.45, dd	2.45, dd	2.25, dd	
•	(× 2)	(13.4, 8)	(13.4, 2)	(13.4, 2)	(13.4, 8)	

Table 1 ¹H NMP

ΗΞ

H

Me

иMe

*This compound was measured at 400 MHz.

†This compound was measured in C_6D_6 .

in 4b was elucidated by measurements of the NOE in C_6D_6 . Irradiation of the C-8 tertiary methyl group (δ 1.47) and H-9 α (2.65) caused 14 and 11% increases in the integrated intensity of the lower field aromatic proton signal (δ 6.51, H-11), respectively. From this NOE data, the configuration of the C-8 position in 4b was elucidated to be *R*. The presence of an acetoxymethyl signal (δ 4.57, 1H, *d*, *J* = 13 Hz; 4.48, 1H, *d*, *J* = 13 Hz and 2.06, 3H, *s*) and no olefinic methyl signal in the ¹H NMR spectrum of 4c indicated that the olefinic methyl group in 4a changed to an acetoxymethyl group. Catalytic hydrogenation of 4b gave a compound 1a and it is assumed that 4b was hydrogenated from the less hindered C-6 β ,7 β side. From the above data, isoschizandrin was elucidated to have the formula 1a.

Anti-ulcer activity was examined in water-immersed rats[6]. All samples were given orally 10 min before the water-immersion. As shown in Table 3, every sample inhibited the development of stress ulcer at 100 mg/kg, though their activities were weaker than that of schizandrin (1b).

EXPERIMENTAL

Mps: uncorr. ¹H NMR spectra were recorded at 60, 100, 200, and 400 MHz using TMS as int. standard. ¹³C NMR spectra were recorded at 50 and 100 MHz using the same int. standard. UV spectra were measured in EtOH, IR spectra in KBr discs. Specific rotations were measured in CHCl₃. Kieselgel 60 (Merck) was used for CC and Kieselgel 60 F₂₅₄ (Merck precoated plate) was used for TLC and prep. TLC. Spots were detected under UV (254 nm).

Isolation of isoschizandrin (1a). In the previous paper [2], it was reported that the petrol and MeOH extracts of the fruits of Schizandra chinensis Baill. (4.671 kg) afforded twelve fractions (frs 1-12) on silica gel CC with *n*-hexane, Me₂CO-benzene, and Me₂CO solvent systems. Fr. 10 (6.07 g) was chromatographed on silica gel (120 g) with an *n*-hexane-Me₂CO solvent system. The *n*hexane-Me₂CO (4:1) eluate (1.623 g) was rechromatographed on silica gel (50 g) with an *n*-hexane-EtOAc solvent system. The *n*-hexane-EtOAc (73:27) and (70:30) eluates (1.153 g) were

purified by repeated prep. TLC [1st: CHCl₃-EtOH (19:1), R_f 0.52; 2nd: *n*-hexane–EtOAc (1:2), R_f 0.51; 3rd: *n*-hexane–Me₂CO (3:2), R_f 0.35] to give isoschizandrin (**1a**) (56 mg, yield 0.0012%) as white amorphous powder, $[\alpha]_{25}^{25} + 92^{\circ}$ (CHCl₃; *c* 1.22). IR ν_{max}^{MB} cm⁻¹: 3480 (OH), 1595, 1575 (aromatic ring). $\nu_{max}^{\text{CHCl}_3}$ cm⁻¹: 3575 (OH), 1591, 1575 (aromatic). UV $\lambda_{max}^{\text{EtOH}}$ nm (log ε): 218 (4.67), 251 (4.19), 284 (sh 3.38). MS m/z (rel. int.): 432 [M]⁺ (2.8), 414 (100), 399 (9), 330 (14). High resolution MS m/z: 432.2198 (calc. for C₂₄H₃₂O₇: 432.2148).

Dehydration of isoschizandrin (1a). Isoschizandrin (1a) (68 mg) was dissolved in a mixture of POCl₃ (0.4 ml) and dry pyridin (1 ml) and the soln heated at 70° for 1 hr. After cooling, the reaction mixture was diluted with Et_2 O and poured into ice H_2 O. The Et_2 O soln was washed with H_2 O, dried over Na_2SO_4 and evapd. The residue was purified by prep. TLC [*n*-hexane–EtOAc (7:3), R_f 0.6] to give a dehydrated compound (2) (36 mg) as colourless prisms from *n*-hexane, mp 115–117°, $[\alpha]_D^{25^\circ}$ + 198° (*c* 0.470, CHCl₃) (Found: C, 69.51; H, 7.33. $\text{C}_{24}\text{H}_{30}\text{O}_6$ requires: C, 69.54; H, 7.30). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 1632 (C=C), 1596, 1576 (aromatic ring). MS *m*/*z* (rel. int.): 414 [M]⁺ (100), 399 (11), 383 (6), 368 (8). ¹H NMR (200 MHz, CDCl₃): δ 1.02 (3H, *d*, *J* = 7 Hz, H–-[–-Me), 2.53 (2H, *m*, ArCH₂–), 2.92 and 3.01 (each 1H, *d*, *J* = 12.5 Hz, ArCH₂–C=C), 2.68 (1H, *m*, --[H), 3.60 (3H, *s*), 3.62 (3H, *s*), 3.87 (3H, *s*), 3.90 (9H, *s*) (6 × OMe), 4.73 and 4.86 (each 1H, *d*, *J*

= 2 Hz, $-\dot{C}$ =CH₂), 6.55 and 6.65 (each 1H, s, 2 × ArH).

Catalytic hydrogenation of 2. Compound 2 (14 mg) in MeOH (2 ml) was hydrogenated in the presence of PtO₂ (25 mg) for 1.5 hr. The reaction mixture was purified by prep. HPLC prep. semi μ -Bondapak C₁₈, 7.8 mm i.d. \times 30 cm; MeCN-MeOH-H₂O (10:10:12); 3.5 ml/min; UV 290 nm] to give 1c (RR_t 26.7 min) (2.5 mg) and 1d (RR_t 24.7 min) (5 mg). Compound 1c. Colourless prisms from n-hexane-Et₂O; mp 114–116°; $[\alpha]_D^{24^\circ} + 80^\circ$ (c 0.25, CHCl₃); IR v_{max}^{KBr} cm⁻¹: 1591, 1576 (aromatic ring); MS m/z (rel. int.): 416 [M]⁺ (100), 370 (6.2), 330 (5.2), 314 (4.8), 235 (6.9). This was identified as (+)deoxyschizandrin by direct comparison (mmp, $[\alpha]_D$, IR, ¹H NMR) with an authentic sample. Compound 1d. Colourless prisms from *n*-hexane; mp 84–86°; $[\alpha]_D^{24^\circ} + 82^\circ$ (c 0.25, CHCl₃).

1a-1e, and 3 in CDCl₃ (200 MHz)

H-7	H-8	C-7-Me	C-8-Me	OMe
		(J = Hz)	(J = Hz)	5
1.89, m	1.78, s	0.89, d	1.19, s	3.56, 3.57, 3.88 (×2)
	(OH)	(7.1)		3.89 (× 2)
1.80, m	(OH)	0.92, d	1.14, s	3.48, 3.49, 3.62
		(7)		3.63, 3.85, 3.86
1.86, s	1.80, <i>m</i>	1.25, s	0.82, d	3.59 (× 2), 3.90 (× 2)
(OH)			(7)	3.92 (×2)
. ,	1.86 (centre)	1.00, d	0.74, d	3.58 (×2), 3.88 (×4)
	(2H, m)	(7)	(7)	
	1.75 (centre)	0.86, d	0.86, d	3.56 (× 2), 3.88 (× 4)
	(2H, m)	(7)	(7)	
1.75, m		0.85, d	0.84, s	3.56 (× 2), 3.88 (× 4)
		(7)		
	1.72 (centre)	0.84, d	0.84, d	$3.80 (\times 2), 5.92 (1H, d,$
				J = 1.22)
	(2H, <i>m</i>)	(7.3)	(7.3)	and 5.95 (1H, d , $J = 1.22$) (OCH ₂ O)

[‡]These compounds were measured at 100 MHz.



Fig. 1. Contour map of the ${}^{1}\text{H}-{}^{13}\text{C}$ shift correlated spectrum of 1a obtained by the COLOC (in CDCl₃). The J_{CH} parameter was set to 0.6 Hz.

(Found: C, 69.10; H, 7.74. $C_{24}H_{32}O_6$ requires: C, 69.21; H, 7.74); IR v_{max}^{KBc} cm⁻¹: 1590, 1570 (aromatic ring); MS m/z (rel. int.); 416 [M]⁺ (100), 370 (6), 314 (7).

Catalytic deuteration of 2. Compound 2 (18 mg) in MeOH- d_4 . (2 ml) was hydrogenated in the presence of PtO₂ (30 mg) for 1 hr. The reaction mixture was purified by prep. HPLC (as described above for the catalytic hydrogenation) to give a minor product (RR_t 26.7 min) (1 mg) and 1e (RR_t 24.7 min) (12 mg) as a white amorphous powder; MS m/z (rel. int.): 419 [M + 1]⁺ (100), 418 [M]⁺ (87), 402 (3); ¹H NMR: Table 1.

Dehydration of schizandrin (1b). Schizandrin (1b) (4 g) was dissolved in a mixture of POCl₃ (4 ml) and dry pyridine (20 ml), and the soln was heated at 90° for 2 hr. After cooling, the reaction mixture was diluted with H_2O and poured into ice H_2O . The Et_2O soln was washed with H_2O , dried over Na_2SO_4 and evapd. The residue was recrystallized from *n*-hexane- Et_2O to afford a dehydrated compound (4a) (2.4 g) as colourless prisms, mp 122-122.5° (Found: C, 69.51; H, 7.39. Calc. for $C_{24}H_{30}O_6$: C, 69.54; H, 7.30). $[\alpha]_B^{25^\circ} - 97^\circ$ (CHCl₃; c 1.07). This was identical (IR, ¹H NMR, MS, $[\alpha]_D$, mp) with an authentic sample [5].

Oxidation of 4a with selenium dioxide. Compound 4a (2.4 g) and selenium dioxide (1.2 g) were dissolved in dioxane (10 ml) and the soln was stirred for 6 hr at 45°. The reaction mixture was diluted with Et_2O , washed with H_2O , dried over Na_2SO_4 and evapd. The residue was chromatographed on silica gel (3 cm i.d. \times 20 cm) with an *n*-hexane–EtOAc solvent system. The fractions eluted with *n*-hexane–EtOAc (60:40) were combined and evapd to give a residue, which was acetylated by the mixture of Ac₂O (1 ml) and dry pyridine (2 ml). The reaction mixture was purified by prep. TLC [*n*-hexane–Me₂CO (7:3)] to give **4b** (R_f 0.3, 285 mg) and **4c** (R_f 0.5, 410 mg). Compound **4b**. Colourless prisms from *n*-hexane–Et₂O; mp 178–180°; $[\alpha]_{D_{3}}^{23}$ – 41° (CHCl₃; *c* 2.36) (Found: C, 66.95; H, 7.18. C₂₄H₃₀O₇ requires: C, 66.96; H, 7.02). IR v^{KBr}_{max} cm⁻¹: 3480 (OH), 1592, 1579 (aromatic ring); UV $\lambda^{\text{max}}_{\text{max}}$ nm (log ε): 211 (4.54), 228 (4.55), 294 (sh 3.33); MS *m*/z (rel. int.): 430 [M]⁺ (100), 412 (33), 399 (11); ¹H NMR (200 MHz,

C₆D₆): δ 1.47 (3H, s, HO-C-Me), 1.54 (1H, br s, OH), 1.76 (3H, s, HC=C-Me), 2.65 (1H, d, J = 13 Hz), 3.24 (1H, d, J = 13 Hz) (ArCH₂-), 3.44 (3H, s), 3.57 (3H, s), 3.62 (3H, s), 3.72 (3H, s), 3.78 (3H, s), 3.85 (3H, s) (6 × OMe), 6.28 (1H, br s, HC=C-Me), 6.45 (1H, s, H-4), 6.51 (1H, s, H-11). Compound 4c yellow oil, $[\alpha]_{B^3}^{B^3}$ - 178° (CHCl₃; c 1.76). C₂₆H₃₂O₈ (high resolution MS: 472.2150; Calc. 472.2097); IR v^{ENP}_{max} cm⁻¹: 1738 (C=O), 1594, 1574 (aromatic ring); UV λ^{EiOH}_{max} nm (log ε): 211 (4.57), 242 (sh 4.35), 288 (sh 3.39); MS m/z (rel. int.): 472 [M] + (100), 412 (5), 381 (24), 300 (18); ¹H NMR (200 MHz, CDCl₃): δ 1.12 (3H, d, J = 7 Hz, -CH-Me), 2.06 (3H, s, COMe), 2.36 (1H, dd, J = 14, 8 Hz), 3.14 (1H, dd, J = 14, 7.5 Hz) (ArCH₂-), 2.88 (1H, m-CH), 3.53 (3H, s), 3.64 (3H, s), 3.86 (3H, s), 3.88 (3H, s), 3.90 (3H, s) (6 × OMe), 4.48 (1H, d, J = 13 Hz), 4.54 (1H, d, J = 13 Hz) (=C-CH₂OCOMe), 6.43 (1H, s, ArH), 6.46 (1H, s, ArH), 6.50 (1H, br s, HC=C-). Catalvtic hydrogenation of **4b**. Compound **4b** (160 mg) in

Catalytic hydrogenation of 4b. Compound 4b (160 mg) in MeOH (3 ml) was hydrogenated in the presence of 10% Pd-C (160 mg) for 7 hr. The reaction mixture was purified by prep. TLC

с	1a*	16	16	1d	3
1	151.7	151.9ª	 151.6ª	151.6	141.2
2	140.3	140.8 ^b	140.3 ^b	140.2	134.9
3	151.8	152.3	153.0	151.6	147.5
4	110.6	110.5°	107.3	110.7	106.1
5	133.65	131.8	139.1	134.2	133.0
6	35.4	40.9	35.7	33.1	32.8
7	40.8	71.8	40.9	36.0	35.9
8	74.1	41.8	33.8	36.0	35.9
9	42.1	34.4	39.2	33.1	32.9
10	133.67	133.8	133.9	134.2	133.0
11	110.4	110.1°	110.6	110.6	106.1
12	152.0	152.0	151.7	151.6	147.5
13	140.5	140.3 ^b	139.9 ^b	140.2	134.9
14	151.7	151.6ª	151.5ª	151.6	141.2
15	123.3	122.8	123.5	123.7	122.4
16	122.9	124.2	122.4	123.7	122.4
17	29.2	15.9	12.7	20.4	20.5
18	13.5	29.7	21.8	20.4	20.5
	C-1,14 60.5 (×2)	60.6 (×2)	60.3 (× 2)	60.5 (×2)	59.6 (× 2)
OMe	C-2,13 60.9 (×2)	61.0 (× 2)	60.7 (× 2)	60.9 (×2)	
	C-3,12 56.0 (× 2)	55.9 (×2)	55.7 (×2)	56.0 (× 2)	
OCH ₂ O					100.7

Table 2. ¹³C NMR spectral data of compounds 1a-1d, and $3 (\delta \text{ in CDCl}_3, 50 \text{ MHz})$

*This compound was measured at 100 MHz and assignments for the carbon signals were confirmed by the ${}^{1}H{-}^{13}C$ shift correlation 2D-NMR spectrum.

^{a,b,c} Assignments within any vertical column may be reversed.

Compound	Dose (mg/kg, p.o.)	Number of rats	Inhibitory ratio (%)
control		5	
1a	100	5	39.9
1b	100	5	52.5
2	100	5	34.1
1c	100	5	30.7
4a	100	5	20.7
4b	100	5	15.9
4c	100	5	25.1
cimetidine	50	5	61.5

Table 3. Effect of schizandrin and its derivatives on water-immersion stress-induced gastric ulcer in rats

[CHCl₃-EtOH (20:1), R_f 0.45] to give product 1a (79 mg) as a white amorphous powder, $[\alpha]_D^{23'} + 90^{\circ}$ (CHCl₃; c0.730) (Found: C, 66.40; H, 7.33. C₂₄H₃₂O₇ requires: C, 66.65; H, 7.46). This was identified as isoschizandrin by direct comparison ($[\alpha]_D$, IR, ¹H NMR, ¹³C NMR) with an authentic sample.

Bioassay. Male Wister strain rats weighing 230-250 g were placed in a stress cage and immersed to the level of the xiphoid process in a water bath (23°) for 7 hr. The animals were then immediately sacrificed by a blow on the head. The stomach of each was removed, slightly inflated by injecting 1% formaline soln for 10 min to flex the inner and outer layers of gastric walls. The stomach was then incised along the greater curvature and examined for lesions developed in the glandular portion. The ulcer index was calculated as the sum of the length (mm) of lesions. Samples were suspended in 1% Tween 80 soln. Cimetidine (100 mg/kg or 50 mg/kg) as a positive control was given orally 10 min before the water-immersion.

Inhibitory ratio (%)

Acknowledgements—We thank Dr M. R. Wälchli, Bruker Japan Co. Ltd, for measurements of 400 MHz NMR spectra, and Mr H. Kobayashi, Faculty of Pharmaceutical Science, University of Tokyo, for measurement of NOE. We also thank Mr K. Sato, Meiji College of Pharmacy for elemental analysis, and Mr I. Sakakibara, Tsumura Laboratory for measurements of mass spectra.

REFERENCES

- Nakajima, K., Taguchi, H., Ikeya, Y., Endo, T. and Yosioka, I. (1983) Yakugaku Zasshi 103, 743.
- 2. Ikeya, Y., Taguchi, H., Yosioka, I. and Kobayashi, H. (1979) Chem. Pharm. Bull. 27, 1383.
- 3. Ikeya, Y., Taguchi, H., Yosioka, I. and Kobayashi, H. (1979) Chem. Pharm. Bull. 27, 2695.
- 4. Takeya, T., Okubo, T., Nishida, S. and Tobinaga, S. (1985) Chem. Pharm. Bull. 33, 3599.
- 5. Ikeya, Y., Taguchi, H., Sasaki, H., Nakajima, K. and Yosioka, I. (1980) Chem. Pharm. Bull. 28, 2414.
- 6. Takagi, K. and Okabe, S. (1968) Jpn J. Pharmacol. 18, 9.